These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 35909271)

  • 1. Antibody-drug Conjugates for Breast Cancer Treatment.
    Sheikh MS; Huang Y
    Recent Pat Anticancer Drug Discov; 2022; 18(2):108-113. PubMed ID: 35909271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Pourjamal N; Yazdi N; Halme A; Joncour VL; Laakkonen P; Saharinen P; Joensuu H; Barok M
    Clin Exp Metastasis; 2024 Apr; 41(2):91-102. PubMed ID: 38367127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
    ;
    Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):913-927. PubMed ID: 36164692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Tesch ME; Gelmon KA
    Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
    Najjar MK; Manore SG; Regua AT; Lo HW
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment-related adverse events associated with antibody drug conjugate in breast cancer].
    Collineau B; Gonçalves A; Bertucci F; de Nonneville A
    Bull Cancer; 2024; 111(7-8):765-781. PubMed ID: 38772845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
    Nguyen X; Hooper M; Borlagdan JP; Palumbo A
    Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer.
    Rassy E; Rached L; Pistilli B
    Breast; 2022 Dec; 66():217-226. PubMed ID: 36334569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer.
    Cherifi F; Da Silva A; Martins-Branco D; Awada A; Nader-Marta G
    Expert Opin Drug Metab Toxicol; 2024; 20(1-2):45-59. PubMed ID: 38214896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low.
    Fan P; Xu K
    Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188849. PubMed ID: 36502928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
    Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
    Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.